亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

滄州那瑞化學科技有限公司  

原料藥、醫藥中間體(格列美脲中間體、多奈哌齊中間體、卡巴拉汀中間體、左乙拉西坦中間體、托拉塞米中間體、維達列汀中間體、沙格列汀中間體、頭孢替坦中間體、西他列汀中間體、格列吡嗪中間體、依帕司他中間體、羅格列酮中間體、吡格列酮中間體、阿格列汀中間體、利拉利汀中間體、瑞格列奈中間體、鹽酸美金中間體、孟魯司特中間體、雷沙吉蘭中間體等)

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:蘭芳
  • 電話:0317-3563899
  • 郵件:trade@senary.com
  • 傳真:0317-3563199
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > (R)-3-Boc-氨基...啶(309956-78-3)
(R)-3-Boc-氨基...啶(309956-78-3)
單價 面議對比
詢價 暫無
發貨 河北滄州市付款后3天內
品牌 那瑞化學
型號 309956-78-3
規格 企業標準
過期 長期有效
更新 2014-03-13 10:10
 
詳細信息
(R)-3-Boc-氨基...啶
中文名稱:(R)-3-Boc-氨基哌...
英文名稱:(R)-3-(Boc-Amino)piperidine
Cas No:309956-78-3
純度:98%
外觀:白色粉末
分子式:C10H20N2O2
分子量:200.28
產品包裝:25kg/紙板桶、鋁箔袋
儲存條件:密封陰涼干燥通風保存
用途:(R)-3-Boc-氨基...啶用作利拉利汀中間體。

©2025 滄州那瑞化學科技有限公司 版權所有   技術支持:化工網   訪問量:11926  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |